Stocks Leading in March. In this article, we are going to take a look at where Mineralys Therapeutics, Inc. (NASDAQ:MLYS) ...

Researchers have discovered that a common form of high blood pressure is caused by tiny, non-cancerous growths in the adrenal ...

In current European and American revascularization guidelines, RA grafts are now strongly endorsed as the second conduit for ...

Two pivotal trials of the aldosterone synthase inhibitor have shown positive results for lorundrostat in uncontrolled and ...

Lorundrostat demonstrated strong efficacy and safety in the pivotal Phase 3 Launch-HTN and Phase 2 Advance-HTN trials. These ...

We recently compiled a list of the 10 Pump and Dump Stocks Favored by Hedge Funds. In this article, we are going to take a ...

Addison’s disease is a rare condition in which the adrenal glands do not produce enough of the hormones cortisol and ...

BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities acted as joint book-running managers for the offering. LifeSci Capital acted as lead manager and H.C.

Topline data were announced from a trial investigating lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension.

Spironolactone's safety profile had been primarily generated from trials of older people with heart failure, so its safety in ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in a pair of clinical trials.